To inspire and empower millions of people living with Parkinson’s around the world, Bial launches a touching campaign for the World Parkinson’s Day showing that it is possible to live a normal life, and successfully perform everyday tasks
Imagine being unable to control your own body. In your mind, everything is exactly like it was; but your brain seems to have forgotten how to tell your body to do everyday tasks like tying up shoes or using a toothbrush.
This is how it feels to live with Parkinson’s. A real challenge for the 10 million people diagnosed with Parkinson’s around the world. Parkinson’s is a progressive neurodegenerative disease – an illness that affects nerve cells in the brain. For those who live with these symptoms and for their families, Parkinson’s means much more than just physical symptoms: it also means a loss of their independence.
In order to raise awareness and help people keep their self-esteem, people with Parkinson’s were invited to star in a video that shows them at their best by focusing on what they can do instead of what they cannot do. Buttoning up shirts, putting on make-up, tying up shoes or even dancing and playing musical instruments. Simple, everyday tasks alongside a cheerful, feel-good tune developed specially for the campaign.
António Portela, CEO of Bial, explains the positive tone of the campaign: “Parkinson’s can really change people’s lives, but it’s very important that they do not lose their self-esteem. That is why we wanted to counter the negative portraits of people with Parkinson’s and show everyone what they really can do. Hopefully, we can inspire and empower the millions of people living with Parkinson’s to never give up on their dignity. Bial’s aim is to help the lives of people with Parkinson’s even if it’s to help with one small thing at a time.”
The campaign launches worldwide today – on World Parkinson’s Day – and is featured on Bial’s website, across Bial’s social media and on the European Parkinson’s Disease Association’s social media channels too.
Watch the video ‘Me at my best’ below
This article is sponsored by Bial. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Founded in 1924, Bial’s mission is to discover, develop and provide therapeutic solutions within the area of health. In recent decades, Bial has strategically focused on quality, innovation and internationalisation. Bial has channelled more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system.
In 2016 Bial launched Opicapone for Parkinson’s disease. Already available in Germany and in the United Kingdom, it will be introduced in the remaining European countries throughout 2017.
Currently representing around two thirds of its turnover, Bial will continue to strengthen its international presence based in its own innovative medicines, particularly in the most important European pharmaceutical markets, Spain, Germany, United Kingdom and Italy, where the company is already present with its own affiliates. For more information about Bial, please visit www.bial.com.
DBS: “We are moving past the idea that one treatment fits all”
How Medtronic is tailoring DBS treatment to individual patients
3 days ago
New biotech to drive forward GDNF treatment for Parkinson’s disease
UK charity Parkinson’s UK is creating a new company, Vivifi Biotech, to develop a treatment with potential to stop or reverse Parkinson’s disease. The experimental therapy surgically distributes GDNF, a protein that is naturally produced by the brain to protect cells, directly into the brain. The charity previously funded a clinical trial to investigate whether boosting GDNF levels could regenerate dying brain cells in people with Parkinson’s. Over the next two years, it will invest up to £800,000 to prepare for a second trial. Arthur Roach, head of research at Parkinson’s UK, said: “While our initial trial didn’t meet its critical endpoint, it did reveal robust evidence indicating that GDNF can possibly reverse Parkinson’s. This is why Parkinson’s UK is committed to continuing research into this potential treatment.” Vivifi Biotech, Roach added, will “bring the right people together to plan a new trial that meets the needs of patients, regulatory…
New wearable medical device for Parkinson’s disease to launch this year
The Imperial College London Innovation Fund, UK, has invested £205,000 to support UK-based tech company Charco Neurotech in its development of a non-invasive medical device for people with Parkinson’s disease. CUE1, a circular device that attaches to the sternum with medical adhesives, uses specialised vibration to help alleviate physical symptoms of Parkinson’s disease. Initial user testing among people with the condition found that the device improved movement by an average of 16%, with testers reporting benefits for walking and fine motor tasks. Lucy Jung, CEO and co-founder of Charco Neurotech, said: “We believe that CUE1 has the potential to significantly improve [Parkinson’s disease] symptoms through its unique controlled vibration technology. We are excited to continue our work on the device and we look forward to the outcome of our proposed clinical trials.” Charco Neurotech will use the Imperial College investment to initiate a clinical trial and fund the device’s manufacture for…
New study brings scientists a “vital step” closer to understanding Parkinson’s disease
A new study from scientists at the University of Cambridge, UK, has brought researchers “a vital step” closer to discovering the origins of Parkinson’s disease. The research, published in the scientific journal ‘Nature Communications’, offered insights on the protein alpha-synuclein, which clumps together in the neurons of people with Parkinson’s. The study focused on how the protein functions in those without the condition and revealed that it sticks to the inner side of the plasma membrane of nerve cells, but not the outer membrane – an insight that could help in the search for a cure. Lead study author, Dr Giuliana Fusco, said: “This study could unlock more information about this debilitating neurodegenerative disorder that can leave people unable to walk and talk. If we want to cure Parkinson’s, first we need to understand the function of alpha-synuclein, a protein present in everyone’s brains.”